Determination of Regulatory Review Period for Purposes of Patent Extension; BRINSUPRI
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BRINSUPRI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.
What this item does
The short version, using the agency's own summary text.
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BRINSUPRI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.
Notice.
Important dates
The dates that matter most for this item.
Published
August 10, 2026
Comment deadline
February 8, 2027
Who published it
The agencies listed in the official filing.